Sign in:
 Email
 Password  save:
  
 Company Reports 
 
 
Membership is free, please Sign Up.
  
My Recent Searches
  Help
  
   
 
 
Get Insiders for : 
Vertex Pharmaceuticals Inc (VRTX)  
$428.59 1.34 (0.31%) as of 4:30 Tue 5/14


Download
   
Exchange: Nasdaq National Market
Security Type: Common
Shares Out: 260,040,000
Market Cap: 111.45(B)
Last Volume: 935,882 Avg Vol: 1,615,310
52 Week Range: $323.57 - $446.08
Level I Sector: Health Care
Level II Sector: Drugs
Level III Sector: Drug Manufacturers - Other

Member Indexes:
    S&P COMPOSITE 1500     NASDAQ BIOTECHNOLOGY
    NASDAQ COMPOSITE     NASDAQ-100
    S&P 400 MIDCAP     NASDAQ NNM COMPOSITE

Rankings:
     
Insider 3 Months    :   -
Insider 6 Months    :   -
Insider 3/6 Months :   -
Guru Rank Number :  543
Guru Rank Value     : 3
Guru Occurances    : 1

 

            6 Months   1 Year   2 Year  
 
Company Profile   Vertex Pharmaceuticals is a biotechnology company. Co. has clinical and research programs to develop treatment of cystic fibrosis. In addition, Co. has a pipeline of investigational therapies in other diseases where it is utilizing insight into causal human biology, including sickle cell disease, beta thalassemia, APOL1-mediated kidney disease, type 1 diabetes, pain, alpha-1 antitrypsin deficiency, and muscular dystrophies. Co.'s marketed CF medicines are TRIKAFTA/KAFTRIO (elexacaftor/tezacaftor/ivacaftor and ivacaftor), SYMDEKO/SYMKEVI (tezacaftor in combination with ivacaftor), ORKAMBI (lumacaftor in combination with ivacaftor) and KALYDECO (ivacaftor).

 
 
Summary  (Direct Transactions Only) 3 Months 6 Months 12 Months 24 Months
Total Shares Bought 0 0 0 0
Total Buy Value $0 $0 $0 $0
Total People Bought 0 0 0 0
Total Buy Transactions 0 0 0 0
Total Shares Sold 45,457 125,099 237,443 597,852
Total Sell Value $19,193,323 $51,578,069 $92,174,963 $199,924,371
Total People Sold 8 11 14 18
Total Sell Transactions 19 38 60 128
End Date 2024-02-15 2023-11-14 2023-05-16 2022-05-16

   
Records found: 3266
  Page 1 of 131  
Filer's Name Relation Title Off-Dir-10% Tran. Date Form Action Price Mkt Value D/I Shares Holdings
Rank

  
3m +/-  
Form
   Bhatia Sangeeta N. Director   –       •      –    2024-05-02 4 AS $402.95 $188,178 D/D (467) 4,435 6%     
   Carney Lloyd Director   –       •      –    2024-05-01 4 A $0.00 $0 D/D 1,001 6,319     -
   Bhatia Sangeeta N. Director   –       •      –    2024-05-01 4 A $0.00 $0 D/D 1,001 4,902     -
   Thornberry Nancy Director   –       •      –    2024-05-01 4 A $0.00 $0 D/D 501 1,637     -
   Mckenzie Diana Director   –       •      –    2024-05-01 4 D $0.00 $0 D/D (1,168) 2,436     -
   Mckenzie Diana Director   –       •      –    2024-05-01 4 A $0.00 $0 D/D 1,001 3,604     -
   Upadhyay Suketu Director   –       •      –    2024-05-01 4 D $0.00 $0 D/D (1,168) 2,559     -
   Upadhyay Suketu Director   –       •      –    2024-05-01 4 A $0.00 $0 D/D 1,001 3,727     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-04-02 4 AS $419.00 $100,560 D/D (240) 7,500 3%     
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-04-01 4 D $418.10 $94,073 D/D (225) 7,740     -
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-26 4 AS $425.70 $1,278,803 D/D (3,004) 55,325 -2%     
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-26 4 AS $425.70 $150,698 D/D (354) 55,804 -2%     
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-26 4 AS $425.70 $1,804,542 D/D (4,239) 25,813 -2%     
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-26 4 AS $425.70 $375,893 D/D (883) 15,972 -2%     
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-26 4 AS $425.70 $2,142,974 D/D (5,034) 49,691 -2%     
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-26 4 AS $425.70 $375,893 D/D (883) 7,965 -2%     
   Sachdev Amit EVP Chief Patient & Ext Af Off   •       –      –    2024-02-23 4 D $431.79 $1,066,090 D/D (2,469) 58,329     -
   Tatsis Ourania EVP, Chief Reg. & Quality Off.   •       –      –    2024-02-23 4 D $431.79 $1,428,793 D/D (3,309) 56,158     -
   Altshuler David EVP, Global Research and CSO   •       –      –    2024-02-23 4 D $431.79 $1,714,206 D/D (3,970) 30,052     -
   Atkinson Edward Morrow Iii EVP, Chief Technical Ops. Off.   •       –      –    2024-02-23 4 D $431.79 $714,181 D/D (1,654) 16,855     -
   Bozic Carmen EVP and CMO   •       –      –    2024-02-23 4 D $431.79 $1,428,793 D/D (3,309) 36,939     -
   Arbuckle Stuart A EVP, COO   •       –      –    2024-02-23 4 D $431.79 $2,035,458 D/D (4,714) 54,725     -
   Ambrose Kristen SVP & Chief Accounting Officer   •       –      –    2024-02-23 4 D $431.79 $357,522 D/D (828) 8,848     -
   Kewalramani Reshma CEO & President   •       •      –    2024-02-23 4 D $431.79 $4,052,781 D/D (9,386) 136,507     -
   Wagner Charles F Jr EVP & Chief Financial Officer   •       –      –    2024-02-23 4 D $431.79 $1,428,793 D/D (3,309) 53,583     -
  3266 Records found
  1  2  3  4  5  6  7  8  9  Next   
  Page 1 of 131
  Transaction Code Key: Ownership Code Key
  B - Buy AB - Automatic Buy D - Direct Ownership
  S - Sell AS - Automatic Sell I - Indirect Ownership
  OE - Options Exercised A - Acquired
  IO - Initital Ownership D - Disposed
 
 
    Copyright © 2024 j3sg.com | Disclaimer & Terms of use          Products & Service  About Us  Contact Us